TRANBERG® Transperineal MR/US Fusion Laser--Induced Thermal Therapy for Men With Prostate Cancer

This study is set up as a phase I prospective, single center, device interventional pilot study carried in office setting under local anesthesia. It will assess the tolerance and safety of target fusion ablation of prostate cancer tumors using Laser Induced Thermal Therapy (TFA-LITT) guided by fusion imaging in men 50 to 80 years of age with low to intermediate risk prostate cancerProstate Cancer is currently managed with in a discrete fashion where patients either enroll in active surveillance protocols (No intervention) or undergo full intervention via whole gland treatments - most commonly radical surgery or radiation. These treatments have not shown definitive gains in all cause survival and not uncommonly harbor undesirable adverse effects, most notably: impotency and incontinence. Such events elicit significant and noticeable changes on a male lifestyle and for most prostate cancer tumors are considered overtreatment. This study aims to evaluate the use of TFA-LITT in the office setting under local anesthesia - greatly decreasing patient perioperative surgical risk - focused on the organ sparing cancer lesion ablation, where organ function is preserved.The fundamental objective is to determine the tolerance and safety of TFA-LITT in men with low to intermediate risk prostate cancer, successful performed in the outpatient office-based setting under local anesthesia directed by fusion imaging. Secondary objectives include: 1-Biopsy proven cancer control of ablated areas 12 months after procedure; 2-Uroflowmetry and urinary function Patient Reported Outcome Measures (PROMs) at one, three, six, nine and 12 months; 3- Sexual function Patient Reported Outcome Measures (PROMs) at one, three, six, nine and 12 months; 4- MRI changes of ablated area one, three and 12 months after TFA-LITT; 5- Absence or presence of ejaculation after TFA-LITT.

Inclusion Criteria:Willing and able to sign informed consentSubject is able and willing to complete all procedure and follow-up visits indicated in the protocolAbsence of urinary retentionProstate volume: ≥ 18 and ≤ 100 cc, measured by transrectal ultrasoundSerum creatinine levels <2 ng/dl and GFR > 45Serum PSA levels < 20 ng/mlMultiparametric prostate MRI with piRADS scores 3-5Prostate volume: ≥ 18 and ≤ 100 cc, measured by MRIPresence of Intermediate risk prostate cancer with a volume that is less than 1/3 of the gland volume by MRI evaluationExclusion Criteria:Post-void residual (PVR): > 250 mL or > 50% of voided volumePrevious prostate cancer intervention (Radiation therapy, brachytherapy, prostate cryoablationMajor neurological conditions such as Alzheimer's, Parkinson, Multiple sclerosis, ALS, spinal cord injuryEvidence of neurogenic bladder determined by urodynamics studiesPresence of Indwelling Foley catheter or on active regime of clean intermittent catheterization (CIC) in the prior 30 daysActive urinary tract infection determined by urinary culturesSHIM score <14IPSS score >23Acute prostatitisMacroscopic hematuria without a known contributing factorHistory of colorectal carcinoma with anterior perineal resection of rectumHistory of pelvic radiation therapy or radical pelvic surgeryHistory of bladder neck contracture and/or urethral strictures within the 5 years prior to the informed consent dateBladder stonesMedical contraindication for undergoing TPFLA surgery (eg, infection, coagulopathy, significant cardiac or other medical risk factors for surgery)Diagnosed or suspected bleeding or coagulopathic disorder such as hemophilia, ITP, TTPMedical contraindication to being subjected to local anesthesia